VIRGINIA RETIREMENT SYSTEMS ET Al Decreases Position in Merck & Co., Inc. $MRK

VIRGINIA RETIREMENT SYSTEMS ET Al lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,356,338 shares of the company’s stock after selling 151,000 shares during the quarter. Merck & Co., Inc. comprises approximately 0.8% of VIRGINIA RETIREMENT SYSTEMS ET Al’s portfolio, making the stock its 13th biggest position. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Merck & Co., Inc. were worth $142,768,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MRK. DLD Asset Management LP lifted its holdings in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $585,192,000. Invesco Ltd. lifted its holdings in shares of Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck highlighted new long-term oncology data and more than 100 ASCO 2026 abstracts spanning over 25 cancer types, underscoring the depth of its KEYTRUDA-driven pipeline and giving investors fresh reasons to stay constructive on the growth outlook. Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
• Positive Sentiment: Merck expanded KEYTRUDA collaborations with Erasca and Inhibrx, including a new trial collaboration and encouraging interim Phase 2 results that could advance into Phase 3, signaling continued external validation of its oncology franchise. Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
• Positive Sentiment: Analysts and commentary continue to point to Merck’s growth drivers, with reports emphasizing pipeline strength and Keytruda-related momentum after the company beat quarterly revenue expectations. Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth
• Neutral Sentiment: Citi reinstated Merck with a Neutral rating and a $125 price target, suggesting limited near-term upside despite a still-supportive valuation backdrop. Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target
• Neutral Sentiment: Zacks noted that investors are weighing Merck’s earnings beat against pipeline setbacks and weakness in Gardasil, creating a mixed fundamental picture rather than a clean catalyst. Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
• Negative Sentiment: Merck continues to face pressure from patent-expiry concerns and commentary about slowing parts of the portfolio, which can limit enthusiasm even after recent positive trial and sales updates. Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds

Wall Street Analyst Weigh In

MRK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Cantor Fitzgerald raised their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Finally, UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $112.40 on Wednesday. The business’s 50-day moving average is $116.47 and its two-hundred day moving average is $108.83. The company has a market capitalization of $277.60 billion, a P/E ratio of 31.66, a P/E/G ratio of 2.51 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.